2. Search Result
Search Result
Results for "

LCN2

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

7

Recombinant Proteins

2

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-Q45780
    ZINC00640089
    2 Publications Verification

    		 Akt Cancer
    ZINC00640089 is a specific Lipocalin-2 (LCN2) inhibitor. ZINC00640089 inhibits cell proliferation, cell viability and reduces AKT phosphorylation levels in SUM149 cells. ZINC00640089 has good potential for research in inflammatory breast cancer (IBC) .
    ZINC00640089
  • HY-148364
    ZINC00784494
    2 Publications Verification

    		 Lipocalin Family Akt Cancer
    ZINC00784494 is a specific Lipocalin-2 (LCN2) inhibitor. ZINC00784494 inhibits cell proliferation, cell viability and reduces AKT phosphorylation levels in SUM149 cells. ZINC00784494 has good potential for research in inflammatory breast cancer (IBC) .
    ZINC00784494
  • HY-RS07557
    LCN2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    LCN2 Human Pre-designed siRNA Set A contains three designed siRNAs for LCN2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    LCN2 Human Pre-designed siRNA Set A
    LCN2 Human Pre-designed siRNA Set A
  • HY-164959
    ZINC00230567

    		Lipocalin Family Cancer
    ZINC00230567 is an inhibitor for Lipocalin-2 (LCN2). ZINC00230567 reduces the colony formation and cell viability of cell SUM149, and exhibits anti-tumor efficacy .
    ZINC00230567
  • HY-158049
    Anticancer agent 199

    		Apoptosis Ferroptosis Cancer
    Anticancer agent 199 (Compound G-4) induces apoptosis in triple negative breast cancer (TNBC) cells via the mitochondrial pathway through inhibiting EGFR, AKT and MAPK pathways. Anticancer agent 199 also induces Ferroptosis by down-regulating LCN2. Anticancer agent 199 inhibits TNBC cell viability and migration, and induces S phase cell cycle arrest. Anticancer agent 199 is a derivate of cyclin-dependent kinase inhibitor Rocovitine .
    Anticancer agent 199
  • HY-132195
    RORγt inverse agonist 14

    		ROR Inflammation/Immunology
    RORγt inverse agonist 14 (8e) is a potent, orally active and selective RORγt inverse agonist (EC50 of 2.5 nM) with anti-inflammatory activity. RORγt inverse agonist 14 is used in the study for rheumatoid arthritis and psoriasis .
    RORγt inverse agonist 14

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: